|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||65.76 - 68.49|
|52 Week Range||65.76 - 109.98|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||17.35|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||106.94|
Celgene Corporation (CELG) will present a business update and provide 2019 financial guidance at the 37th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 7:30 a.m. PT/ 10:30 a.m. ET. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
Investing.com - U.S. futures pointed to a flat to lower open on Monday amid trade concerns and worries over a global economic slowdown .The S&P 500 futures dipped 3 points or 0.12% to 2,602.38 as of 6:40 AM ET (11:40 GMT) while Dow futures ticked down 33 points, or 0.14%, to 24,095. Meanwhile tech heavy Nasdaq 100 futures decreased 6 points, or 0.09%, to 6,616.25.All three indexes closed on Friday in correction territory for the first time since March 2016.Trade tensions between the U.S. and China weighed on markets after U.S. ...
10 programs selected to help support healthcare capacity building in resource-constrained countries
Celgene Corporation (NASDAQ:CELG) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of CELG, Read More...
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
The last few years have been a difficult ride for investors in large-cap biotech Celgene ( CELG ). Celgene is currently trading around $68 per share and has a market capitalization of $48 billion. Warning! GuruFocus has detected 2 Warning Signs with CELG.
Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock picks. Investors looking for the best stocks to buy for 2019 should start with these 19 companies. These firms, ranging from a money-center bank to a bargain-basement retailer, have solid prospects in 2019. We've also listed five stocks you should consider parting ways with. Check them out. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. ...
Anheuser-Busch InBev (BUD), International Business Machines Corp. (IBM), Celgene Corp. (CELG) and American International Group Inc. (AIG) have declined to their three-year lows
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
Investing.com - Health care stocks took a dive midday after medical device company Cooper posted lower-than-expected results.